Unity Biotechnology, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Unity Biotechnology's Q1 2025 results reveal ongoing losses and raise substantial doubt about the company's ability to continue as a going concern, despite progress in clinical trials.
Unity Biotechnology's Q3 2024 report reveals ongoing losses and substantial doubt about its ability to continue as a going concern, despite progress in clinical trials.
Unity Biotechnology, a clinical-stage biopharmaceutical company, released its second quarter 2024 financial results, highlighting ongoing clinical programs and a focus on ophthalmology.
Unity Biotechnology reported a net loss of $5.8 million for the first quarter of 2024, while continuing to advance its lead drug candidate UBX1325 through clinical trials for diabetic macular edema.